During the past decade, Chungbuk National University Hospital conducted 125 clinical trials. In the 10-year time frame, 125 clinical trials started and 31 clinical trials were completed, i.e. on average, 24.8% percent of trials that started reached the finish line to date. In the past 5 years, 58 clinical trials started and 20 clinical trials were completed. i.e. 34.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chungbuk National University Hospital" #1 sponsor was "Hoffmann-La Roche" with 12 trials, followed by "Boehringer Ingelheim" with 10 trials sponsored, "Janssen Research & Development, LLC" with 7 trials sponsored, "Daiichi Sankyo, Inc." with 6 trials sponsored and "Yuhan Corporation" with 6 trials sponsored. Other sponsors include 126 different institutions and companies that sponsored additional 87 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chungbuk National University Hospital" #1 collaborator was "AstraZeneca" with 7 trials as a collaborator, "CardioVascular Research Foundation, Korea" with 6 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 6 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator and "Korean Cancer Study Group" with 3 trials as a collaborator. Other collaborators include 63 different institutions and companies that were collaborators in the rest 61 trials.

According to Clinical.Site data, the most researched conditions in "Chungbuk National University Hospital" are "Carcinoma, Non-Small-Cell Lung" (11 trials), "Coronary Artery Disease" (8 trials), "Non-Small Cell Lung Cancer" (8 trials), "Breast Cancer" (7 trials) and "Hypertension" (7 trials). Many other conditions were trialed in "Chungbuk National University Hospital" in a lesser frequency.

Most popular intervention types in "Chungbuk National University Hospital" are "Drug" (147 trials), "Biological" (9 trials), "Device" (8 trials), "Other" (7 trials) and "Dietary Supplement" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (28 trials), "Atezolizumab" (10 trials), "Carboplatin" (10 trials), "Paclitaxel" (10 trials) and "Pembrolizumab" (7 trials). Other intervention names were less common.

The vast majority of trials in "Chungbuk National University Hospital" are 155 trials for "All" genders, 11 trials for "Male" genders and 6 trials for "Female" genders.

Currently, there are NaN active trials in "Chungbuk National University Hospital". undefined are not yet recruiting, 34 are recruiting, 36 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 71 completed trials in Chungbuk National University Hospital, undefined suspended trials, and 14 terminated clinical trials to date.

Out of the total trials that were conducted in Chungbuk National University Hospital, 37 "Phase 1" clinical trials were conducted, 34 "Phase 2" clinical trials and 67 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 16 trials, and there were also 5 trials that are defined as “Not Applicable".